PS0009

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis

Brief summary

This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).

Medical Condition

Psoriatic Arthritis

Min. Age

18
Years

Max. Age

-

Who Can Join?

All

Status

Active, not recruiting
Inclusion criteria

- Must be at least 18 years of age - Chronic plaque psoriasis (PSO) for at least 6 months prior to the Screening Visit - Psoriasis Area Severity Index (PASI) >=12 and body surface area (BSA) affected by PSO >=10% and Investigator’s Global Assessment (IGA) score >=3 on a 5-point scale - Subject is a candidate for systemic PSO therapy and/or phototherapy - Female subject of child bearing potential must be willing to use highly effective method of contraception

Exclusion criteria

- Subject has an active infection (except common cold), a recent serious infection, or a history of opportunistic or recurrent chronic infections - Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection - Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection - Subject has any other condition, including medical or psychiatric, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study - Presence of active suicidal ideation or positive suicide behavior - Presence of moderately severe major depression or severe major depression - Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer

Study Medication Description

Study Medication:

Bimekizumab

Other Descriptive Name:

金禾娱乐城4940

Placebo

Yes

Comparator:

No

Study Dates

December 2017

Actual Start Date of Enrollment

January 2020

Planned Study Completion Date

General Information

Study ID:
PS0009
EudraCT Number:
CT.gov Number:
Phase:
Phase 3

Locations

Interested in our clinical studies?

Just contact us

Austria

金禾娱乐城Cares.AT@ucb.com
+43 (0) 1 291 80 08
0800-296176 (freephone)

Belgium

金禾娱乐城Cares.BE@ucb.com
+32 2 559 92 00
0800 38 008 (freephone)

Bulgaria

Canada

+1 866 709 8444

Czech Republic

金禾娱乐城Cares.CZ@ucb.com
+420 221 773 442
800 144 395 (freephone)

Denmark

金禾娱乐城Cares.DK@ucb.com
+45 32462480
80 253827 (freephone)

Finland

金禾娱乐城Cares.FI@ucb.com
+358 942733300
0800 9 13353 (freephone)

France

金禾娱乐城Cares.FR@ucb.com
+33 1 47 29 45 55
0 805 222 949 (freephone)

Germany

Greece

金禾娱乐城Cares.GR@ucb.com
+30 21 0997 4200
0080 012 9910 (freephone)

Hungary

金禾娱乐城Cares.HU@ucb.com
+36 1 472 5060
06 80 021 486 (freephone)

Ireland

金禾娱乐城Cares.IE@ucb.com
+353 1 463 2371
1800 93 00 75 (freephone)

Italy

金禾娱乐城Cares.IT@ucb.com
+39 02 3007 9300
8009-86932 (freephone)

Japan

Luxemburg

金禾娱乐城Cares.LU@ucb.com
+32 2 559 92 12
8002 3204 (freephone)

Norway

金禾娱乐城Cares.NO@ucb.com
+45 32462482
800-10101 (freephone)

Poland

金禾娱乐城Cares.PL@ucb.com
+48 22 596 97 97
00 800 121 68 25 (freephone)

Portugal

金禾娱乐城Cares.PT@ucb.com
+351 213 025 300
800-8-56033 (freephone)

Romania

+4021 300 19 07

Slovakia

金禾娱乐城Cares.SK@ucb.com
+421 2 592 020 23
0800 002 566 (freephone)

Spain

金禾娱乐城Cares.ES@ucb.com
+34 915 70 06 49
8000-99684 (freephone)

Sweden

金禾娱乐城Cares.SE@ucb.com
+45 32462481
0200 898 671 (freephone)

Switzerland

+41 58 822 3180

The Netherlands

金禾娱乐城Cares.NL@ucb.com
+31 76 573 1130
0800 3434335 (freephone)

UK

金禾娱乐城Cares.UK@ucb.com
+44 1753 777 100
0800 279 3177 (freephone)

USA